H.C. Wainwright analyst Ed Arce maintained a Buy rating on Durect (DRRX – Research Report) today and set a price target of $6.00. The company's shares closed last Tuesday at $0.60, close to its 52-week low of $0.58. According to TipRanks.com, Arce is a 4-star analyst with an average return of 11.2% and a 36.0% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals. Currently, the analyst consensus on Durect is a Moderate Buy with an average price target of $6.00. See the top stocks recommended by analysts >> The company has a one-year high of $2.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-durects-stock-is-going-to-recover?utm_source=advfn.com&utm_medium=referral
Durect (NASDAQ:DRRX)
Historical Stock Chart
From Nov 2022 to Dec 2022 Click Here for more Durect Charts.
Durect (NASDAQ:DRRX)
Historical Stock Chart
From Dec 2021 to Dec 2022 Click Here for more Durect Charts.